Muley, T.;Schneider, M.;Meister, M.;Thomas, M.;Heussel, C.;Kriegsmann, M.;Holdenrieder, S.;Wehnl, B.;Rolny, V.;Mang, A.;Gerber, R.;Herth, F.
Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
J Thorac Oncol
2021
16 Suppl S
10
S1028-S1029

Nassar, Y. M.;Ojara, F. W.;Holdenrieder, S.;Krueger, K.;Joerger, M.;Michelet, R.;Huisinga, W.;Kloft, C.
Prognostic impact of five serum biomarkers in patients with advanced non-small cell lung cancer (NSCLC): An exploratory analysis
Ann Oncol
2021
32 Suppl 5
S404-S404

Saafan, Hisham;Alahdab, Ahmad;Michelet, Robin;Gohlke, Linus;Ziemann, Janine;Holdenrieder, Stefan;McLaughlin, Katie-May;Wass, Mark N;Cinatl, Jindrich;Michaelis, Martin;Kloft, Charlotte;Ritter, Christoph A
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Cells
2021
10
4

Oezcueruemez, Mustafa;Katsounas, Antonios;Holdenrieder, Stefan;von Meyer, Alexander;Renz, Harald;Woelfel, Roman
Assessment of SARS-CoV-2 rapid antigen tests
J. Lab. Med.
2021
45
3
143-148

Sanin, Veronika;Schmieder, Raphael;Ates, Sara;Schlieben, Lea Dewi;Wiehler, Jens;Sun, Ruoyu;Decker, Manuela;Sander, Michaela;Holdenrieder, Stefan;Kohlmayer, Florian;Friedmann, Anna;Mall, Volker;Feiler, Therese;Dreßler, Arne;Strom, Tim M;Prokisch, Holger;Meitinger, Thomas;von Scheidt, Moritz;Koenig, Wolfgang;Leipold, Georg;Schunkert, Heribert
Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study.
Eur J Public Health
2022
32
3
422-428

Ndrepepa, Gjin;Holdenrieder, Stefan;Bernlochner, Isabell;Kastrati, Adnan
Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes.
Clin Res Cardiol
2022
111
7
838-842

Garrido, Manuel M;Marta, José C;Ribeiro, Ruy M;Pinheiro, Luís C;Holdenrieder, Stefan;Guimarães, João T
Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
In Vivo
2021
35
6
3431-3439

van Rossum, Huub H;Meng, Qing H;Ramanathan, Lakshmi V;Holdenrieder, Stefan
A word of caution on using tumor biomarker reference change values to guide medical decisions and the need for alternatives.
Clin Chem Lab Med
2022
60
4
553-555

Garrido, Manuel M;Ribeiro, Ruy;Pinheiro, Luís C;Holdenrieder, Stefan;Guimarães, João T
The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
Clin Chem Lab Med
2021
59
11
1869-1877

Garrido, Manuel M;Bernardino, Rui M;Marta, José C;Holdenrieder, Stefan;Guimarães, João T
Tumour markers in prostate cancer: The post-prostate-specific antigen era.
Ann Clin Biochem
2022
59
1
46-58